Public Profile

Graybug Vision, Inc.

Graybug Vision, Inc., a pioneering name in the ophthalmic industry, is headquartered in the United States. Founded in 2016, the company focuses on developing innovative therapies for retinal diseases, aiming to transform the treatment landscape for patients suffering from conditions such as age-related macular degeneration and diabetic retinopathy. With a commitment to advancing ocular drug delivery systems, Graybug Vision has made significant strides with its proprietary technologies, including sustained-release formulations that enhance patient compliance and treatment efficacy. The company has garnered attention for its unique approach to drug delivery, positioning itself as a leader in the field. As it continues to expand its operational reach, Graybug Vision remains dedicated to improving vision health and achieving notable milestones in the biopharmaceutical sector.

DitchCarbon Score

How does Graybug Vision, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

23

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Graybug Vision, Inc.'s score of 23 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Let us know if this data was useful to you

Graybug Vision, Inc.'s reported carbon emissions

Graybug Vision, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without reported emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the absence of data may indicate that the company is in the early stages of developing its sustainability strategy or reporting framework. As the industry increasingly prioritises climate action, it is essential for companies like Graybug Vision to establish clear emissions reduction goals and engage in transparent reporting to align with global climate standards.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Graybug Vision, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Graybug Vision, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Graybug Vision, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

GP Pharm, S.A.

ES
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Pharmathen

GR
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Medincell

FR
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Nanomi B.V.

NL
Updated 3 months ago
DitchCarbon Score

Dr Reddys Laboratories

IN
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Viatris

US
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers